Stock Watch: Veklury Peaks And Leaves Gilead In The Lurch
The Pandemic Still Drags On Other Antiviral Sales
Executive Summary
Veklury rescued Gilead’s weak underlying first-quarter performance. But the pandemic and its associated behavioral effects, as well as patent expiries, will continue to drag.